相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clearing drug interferences in myeloma treatment using mass spectrometry
Mindy C. Kohlhagen et al.
CLINICAL BIOCHEMISTRY (2021)
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma
Pieter Langerhorst et al.
CLINICAL CHEMISTRY (2021)
Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins
M. Zajec et al.
CLINICAL CHEMISTRY (2020)
An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins
Joannes F. M. Jacobs et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis
Katherine A. Turner et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification
Marina Zajec et al.
JOURNAL OF PROTEOME RESEARCH (2020)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
Christie P. M. Verkleij et al.
CANCERS (2020)
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
Marina Zajec et al.
HEMASPHERE (2020)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay
Katie L. Thoren et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2019)
A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference
John R. Mills et al.
BLOOD (2018)
Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences
Christopher R. McCudden et al.
CLINICAL BIOCHEMISTRY (2018)
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
Kazunori Murata et al.
CLINICAL BIOCHEMISTRY (2018)
Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies
Marina Zajec et al.
JOURNAL OF PROTEOME RESEARCH (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Carlos Cuesta-Mateos et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Christopher McCudden et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
Niels W. C. J. van de Donk et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab
Helene Caillon et al.
BLOOD (2016)
Clarification of the definition of complete response in multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
International Myeloma Working Group recommendations for global myeloma care
H. Ludwig et al.
LEUKEMIA (2014)
IgBLAST: an immunoglobulin variable domain sequence analysis tool
Jian Ye et al.
NUCLEIC ACIDS RESEARCH (2013)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
分享论文
